DelveInsight’s “Bullous Keratopathy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Bullous Keratopathy, historical and forecasted epidemiology as well as the Bullous Keratopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Bullous Keratopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bullous Keratopathy Market Forecast

Some of the key facts of the Bullous Keratopathy Market Report: 

• The Bullous Keratopathy market size was valued ~USD 13.8 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In 2023, the market size for bullous keratopathy in the US was around USD 7.8 million and is expected to grow with the introduction of new therapies.

• In 2023, the total market size for the EU4 and the UK was estimated at about USD 4.8 million, representing nearly 34% of the total market revenue for the 7MM.

• In 2023, Germany had the largest market among the EU4 and the UK, with around USD 1.3 million, followed by France with about USD 1.1 million, and Italy with nearly USD 0.9 million.

• In April 2024, Emmecell has successfully administered the final dose to the last patient in its Phase I trial in the US, which is assessing the safety and efficacy of EO2002 for corneal edema. A Phase III pivotal study is set to begin in the first quarter of 2025, positioning EO2002 as a potential groundbreaking treatment in this area.

• In 2023, the total diagnosed prevalent cases of bullous keratopathy in the 7MM were around 192 thousand. This figure is anticipated to rise during the forecast period (2024–2034) due to an aging population and a higher frequency of ocular surgeries.

• In 2023, the US represented about 41% of the total diagnosed prevalent cases of bullous keratopathy in the 7MM, while the EU4 and the UK together accounted for nearly 50% of cases, and Japan comprised approximately 9% of the total cases.

• In 2023, the US had the highest number of diagnosed prevalent cases of bullous keratopathy in the 7MM, totaling around 79 thousand cases.

• In 2023, Germany recorded the highest number of diagnosed prevalent cases of bullous keratopathy among the EU4 and the UK, with about 26 thousand cases, followed by France with nearly 22 thousand cases. In contrast, Spain had the lowest incidence, with around 14 thousand cases.

• In 2023, Japan reported around 18 thousand diagnosed prevalent cases of bullous keratopathy, a figure anticipated to change during the forecast period.

• In 2023, the diagnosed prevalent cases of bullous keratopathy in the US included around 30 thousand cases in males and approximately 48 thousand cases in females.

• In 2023, about 39% of bullous keratopathy cases in the UK were male, while 61% were female.

• In 2023, Japan recorded around 7 thousand male cases and 10 thousand female cases of bullous keratopathy, a number anticipated to change during the forecast period.

• Key Bullous Keratopathy Companies: Aurion Biotechnologies, Emmecell, Cellusion, Trefoil Therapeutics, Emmecell, Cellusion, Price Vision Group, and others

• Key Bullous Keratopathy Therapies: VYZNOVA (neltependocel), EO2002, CLS001, TTHX1114 (NM141), EO2002, CLS001, Fluorometholone, and others

• The Bullous Keratopathy epidemiology based on gender analyzed that, females are more affected with Bullous keratopathy than males

• The Bullous Keratopathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bullous Keratopathy pipeline products will significantly revolutionize the Bullous Keratopathy market dynamics.

Bullous Keratopathy Overview

A general word used to describe any condition that affects the cornea is keratopathy. Bullouskeratopathy is one of several varieties of keratopathy, each with unique traits and causes. Bullous keratopathy causes corneal edoema and dysfunctional corneal endothelial cells as a result of fluid-filled blisters on the cornea.

Get a Free sample for the Bullous Keratopathy Market Report: 

https://www.delveinsight.com/report-store/bullous-keratopathy-market

Bullous Keratopathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Bullous Keratopathy Epidemiology Segmentation:

The Bullous Keratopathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Bullous Keratopathy

• Prevalent Cases of Bullous Keratopathy by severity

• Gender-specific Prevalence of Bullous Keratopathy

• Diagnosed Cases of Episodic and Chronic Bullous Keratopathy

Download the report to understand which factors are driving Bullous Keratopathy epidemiology trends @ Bullous Keratopathy Epidemiology Forecast

Bullous Keratopathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bullous Keratopathy market or expected to get launched during the study period. The analysis covers Bullous Keratopathy market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Bullous Keratopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Bullous Keratopathy Therapies and Key Companies

• VYZNOVA (neltependocel): Aurion Biotechnologies

• EO2002: Emmecell

• CLS001: Cellusion

• TTHX1114 (NM141): Trefoil Therapeutics

• EO2002: Emmecell

• CLS001: Cellusion

• Fluorometholone: Price Vision Group

Discover more about therapies set to grab major Bullous Keratopathy market share @ Bullous Keratopathy Treatment Market

Bullous Keratopathy Market Strengths

• Advancements in understanding corneal endothelium function and epithelial cell regeneration have developed pharmacological and less invasive surgical techniques like DSAEK and DMEK.

• The use of advanced diagnostic techniques like slit-lamp examination and ultrasound biomicroscopy has improved bullous keratopathy diagnosis

Bullous Keratopathy Market Opportunities

• With no approved treatment in the US and EU, limited application of corneal transplant, and significant risk of rejections, there is a window of opportunity for pharma companies to develop pharmacological therapies.

• Increasing research activities in the field of ophthalmology may lead to the exploration of different pathways involved in bullous keratopathy.

Scope of the Bullous Keratopathy Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Bullous Keratopathy Companies: Aurion Biotechnologies, Emmecell, Cellusion, Trefoil Therapeutics, Emmecell, Cellusion, Price Vision Group, and others

• Key Bullous Keratopathy Therapies: VYZNOVA (neltependocel), EO2002, CLS001, TTHX1114 (NM141), EO2002, CLS001, Fluorometholone, and others

• Bullous Keratopathy Therapeutic Assessment: Bullous Keratopathy current marketed and Bullous Keratopathy emerging therapies

• Bullous Keratopathy Market Dynamics: Bullous Keratopathy market drivers and Bullous Keratopathy market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Bullous Keratopathy Unmet Needs, KOL’s views, Analyst’s views, Bullous Keratopathy Market Access and Reimbursement 

To know more about Bullous Keratopathy companies working in the treatment market, visit @ Bullous Keratopathy Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Bullous Keratopathy Market Report Introduction

2. Executive Summary for Bullous Keratopathy

3. SWOT analysis of Bullous Keratopathy

4. Bullous Keratopathy Patient Share (%) Overview at a Glance

5. Bullous Keratopathy Market Overview at a Glance

6. Bullous Keratopathy Disease Background and Overview

7. Bullous Keratopathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Bullous Keratopathy 

9. Bullous Keratopathy Current Treatment and Medical Practices

10. Bullous Keratopathy Unmet Needs

11. Bullous Keratopathy Emerging Therapies

12. Bullous Keratopathy Market Outlook

13. Country-Wise Bullous Keratopathy Market Analysis (2020–2034)

14. Bullous Keratopathy Market Access and Reimbursement of Therapies

15. Bullous Keratopathy Market Drivers

16. Bullous Keratopathy Market Barriers

17.  Bullous Keratopathy Appendix

18. Bullous Keratopathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/